Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

PHASE3UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
GIST With D842V Mutated PDGFRA Gene
Interventions
DRUG

Crenolanib

DRUG

Placebo

Trial Locations (23)

19111

Fox Chase Cancer Center, Philadelphia

20133

Istituto Nazionale Tumori, Milan

27710

Duke Cancer Institute, Durham

33136

University of Miami, Miami

68167

Mannheim University Medical Centre, University of Heidelberg, Mannheim

69008

Centre Leon Berard, Lyon

77030

MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Center, Santa Monica

97239

Oregon Health and Science University, Portland

Unknown

Institut Bergonie, Bordeaux

La Timone University Hospital, Marseille

Centre Hospitalier Universitaire (CHU) de Reims, Reims

HELIOS Klinikum Berlin-Buch, Berlin

Universitätsklinikum München, Munich

Policlinico S. Orsola-Malpighi, Bologna

Institut Regina Elena / IFO, Rome

Candiolo Cancer Institute - FPO, IRCCS, Turin

University Hospital The Norwegian Radium Hospital, Oslo

M Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw

Vall d'Hebron University Hospital, Barcelona

Hospital Universitario Puerta de Hierro, Madrid

Hospital Virgen del Rocio, Seville

Fundación Instituto Valenciano de Oncología, Valencia

Sponsors
All Listed Sponsors
collaborator

Centre Leon Berard

OTHER

collaborator

Fox Chase Cancer Center

OTHER

lead

Arog Pharmaceuticals, Inc.

INDUSTRY